{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:38Z","timestamp":1787017058357,"version":"build-2736575974"},"reference-count":66,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,1,23]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To analyse microRNA (miR)-21 distribution and expression at the cellular level in non-small cell lung cancer (NSCLC). MiR-21 is an oncogenic microRNA overexpressed in NSCLC. In previous studies, overexpression of miR-21 was evaluated from the tumour bulk by quantitative reverse transcription PCR with results expressed on average across the entire cell population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used in situ hybridisation and immunohistochemistry to assess the correlation between miR-21 levels and the expression of markers that may be possible targets (epidermal growth factor reaction) or may be involved in its upregulation (phosphatase and tensin homolog (PTEN), p53). The Pearson\u2019s \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      tests was used to assess correlation with clinicopathological data and with miR-21 expression both in tumour and tumour stroma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cytoplasmic staining and expression of Mir-21 were detected in the tumours and in associated stromal cells. Expression was highest in the stroma immediately surrounding the tumour cells and decreased as the distance from the tumour increased. No expression of miR-21 was found in normal lung parenchyma and a significant association was found between tumour localised miR-21 and PTEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Presence of miR-21 in both cell tumour and stromal compartments of NSCLC and the relationship with PTEN confirms miR-21 as a microenvironment signalling molecule, possibly inducing epithelial mesenchymal transition and invasion by targeting PTEN in the stromal compartment possibly through exosomal transport. In situ immunohistochemical studies such as ours may help shed light on the complex interactions between miRNAs and its role in NSCLC biology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-206420","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T17:25:11Z","timestamp":1581701111000},"page":"636-641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["MiR-21, EGFR and PTEN in non-small cell lung cancer: an in situ hybridisation and immunohistochemistry study"],"prefix":"10.1136","volume":"73","author":[{"given":"Irina","family":"Marin","sequence":"first","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Ofek","sequence":"additional","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Institute of Oncology, Tel HaShomer Hospital, Tel Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-486X","authenticated-orcid":false,"given":"Nadia","family":"Prisant","sequence":"additional","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Perelman","sequence":"additional","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Avivi","sequence":"additional","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitit","family":"Lavy-Shahaf","sequence":"additional","affiliation":[{"name":"Israel Center for Disease Control, Ministry of Health, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Onn","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Institute of Oncology, Tel HaShomer Hospital, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Katz","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Barshack","sequence":"additional","affiliation":[{"name":"Pathology Department, Tel HaShomer Hospital, Tel Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2025120520004111000_73.10.636.1","doi-asserted-by":"publisher","DOI":"10.4065\/83.5.584"},{"key":"2025120520004111000_73.10.636.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00616-X"},{"key":"2025120520004111000_73.10.636.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2006.08.028"},{"key":"2025120520004111000_73.10.636.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-579X(03)00038-5"},{"key":"2025120520004111000_73.10.636.5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2018.09.019","article-title":"Emerging microRNAs in cancer diagnosis, progression, and immune surveillance","volume":"438","author":"Harrandah","year":"2018","journal-title":"Cancer Lett"},{"key":"2025120520004111000_73.10.636.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242606799"},{"key":"2025120520004111000_73.10.636.7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia","volume":"15","author":"Yeh","year":"2016","journal-title":"Mol Cancer"},{"key":"2025120520004111000_73.10.636.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.01.025"},{"key":"2025120520004111000_73.10.636.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.4.425"},{"key":"2025120520004111000_73.10.636.10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.105"},{"key":"2025120520004111000_73.10.636.11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.gde.2013.02.009","article-title":"Micrornas and targeted therapy: small molecules of unlimited potentials","volume":"23","author":"Fassan","year":"2013","journal-title":"Curr Opin Genet Dev"},{"key":"2025120520004111000_73.10.636.12","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201208082"},{"key":"2025120520004111000_73.10.636.13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2858"},{"key":"2025120520004111000_73.10.636.14","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.12.14252"},{"key":"2025120520004111000_73.10.636.15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104715"},{"key":"2025120520004111000_73.10.636.16","doi-asserted-by":"publisher","DOI":"10.1042\/BST0370918"},{"key":"2025120520004111000_73.10.636.17","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00018-018-2877-x","article-title":"Overview upon miR-21 in lung cancer: focus on NSCLC","volume":"75","author":"Bica-Pop","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"2025120520004111000_73.10.636.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2013.01.004"},{"key":"2025120520004111000_73.10.636.19","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10132"},{"key":"2025120520004111000_73.10.636.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0137"},{"key":"2025120520004111000_73.10.636.21","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3892\/mmr.2016.4844","article-title":"Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21","volume":"13","author":"Li","year":"2016","journal-title":"Mol Med Rep"},{"key":"2025120520004111000_73.10.636.22","doi-asserted-by":"publisher","DOI":"10.1038\/35042675"},{"key":"2025120520004111000_73.10.636.23","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00739"},{"key":"2025120520004111000_73.10.636.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1305"},{"key":"2025120520004111000_73.10.636.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.03.077"},{"key":"2025120520004111000_73.10.636.26","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.410"},{"key":"2025120520004111000_73.10.636.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905234106"},{"key":"2025120520004111000_73.10.636.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.11.003"},{"key":"2025120520004111000_73.10.636.29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-61779-427-8_5","article-title":"Microrna in situ hybridization","volume":"822","author":"Nielsen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2025120520004111000_73.10.636.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2010.07.002"},{"key":"2025120520004111000_73.10.636.31","first-page":"2777","article-title":"Microrna-21: a promising biomarker for the prognosis and diagnosis of non-small cell lung cancer","volume":"16","author":"Zheng","year":"2018","journal-title":"Oncol Lett"},{"key":"2025120520004111000_73.10.636.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2010.01.018"},{"key":"2025120520004111000_73.10.636.33","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.101741"},{"key":"2025120520004111000_73.10.636.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.09.031"},{"key":"2025120520004111000_73.10.636.35","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6890-14-9","article-title":"High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome","volume":"14","author":"Stenvold","year":"2014","journal-title":"BMC Clin Pathol"},{"key":"2025120520004111000_73.10.636.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095193","article-title":"Mir-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival","volume":"9","author":"Hedb\u00e4ck","year":"2014","journal-title":"PLoS One"},{"key":"2025120520004111000_73.10.636.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-015-0227-0","article-title":"Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"2025120520004111000_73.10.636.38","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.104"},{"key":"2025120520004111000_73.10.636.39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"2025120520004111000_73.10.636.40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody\u2013Drug conjugates for the treatment of solid tumors: clinical experience and latest developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target Oncol"},{"key":"2025120520004111000_73.10.636.41","doi-asserted-by":"crossref","first-page":"33446","DOI":"10.18632\/oncotarget.26002","article-title":"RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models","volume":"9","author":"Wong","year":"2018","journal-title":"Oncotarget"},{"key":"2025120520004111000_73.10.636.42","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.022"},{"key":"2025120520004111000_73.10.636.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039520","article-title":"Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT\/ERK1\/2 inactivation by targeting PTEN","volume":"7","author":"Han","year":"2012","journal-title":"PLoS One"},{"key":"2025120520004111000_73.10.636.44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.057"},{"key":"2025120520004111000_73.10.636.45","doi-asserted-by":"crossref","first-page":"84508","DOI":"10.18632\/oncotarget.13022","article-title":"Mir-21 and miR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget"},{"key":"2025120520004111000_73.10.636.46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12032-014-0057-x","article-title":"High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation","volume":"31","author":"Dong","year":"2014","journal-title":"Med Oncol"},{"key":"2025120520004111000_73.10.636.47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3892\/mco.2018.1603","article-title":"High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma","volume":"8","author":"Yi","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"2025120520004111000_73.10.636.48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7150\/ijbs.22243","article-title":"Micrornas associated with therapy of non-small cell lung cancer","volume":"14","author":"Lu","year":"2018","journal-title":"Int J Biol Sci"},{"key":"2025120520004111000_73.10.636.49","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204031"},{"key":"2025120520004111000_73.10.636.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219597","article-title":"Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-\u00df1 and miRNA21 cooperation","volume":"14","author":"Camerlingo","year":"2019","journal-title":"PLoS One"},{"key":"2025120520004111000_73.10.636.51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073009","article-title":"Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma","volume":"8","author":"Nouraee","year":"2013","journal-title":"PLoS One"},{"key":"2025120520004111000_73.10.636.52","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q"},{"key":"2025120520004111000_73.10.636.53","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.81"},{"key":"2025120520004111000_73.10.636.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2015.02.001"},{"key":"2025120520004111000_73.10.636.55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0897-7"},{"key":"2025120520004111000_73.10.636.56","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1596"},{"key":"2025120520004111000_73.10.636.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209414109"},{"key":"2025120520004111000_73.10.636.58","first-page":"712","article-title":"Upregulated expression of serum exosomal microRNAs as diagnostic biomarkers of lung adenocarcinoma","volume":"48","author":"Feng","year":"2018","journal-title":"Ann Clin Lab Sci"},{"key":"2025120520004111000_73.10.636.59","first-page":"9811","article-title":"Exosome-Mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21","volume":"15","author":"Jing","year":"2018","journal-title":"Oncol Lett"},{"key":"2025120520004111000_73.10.636.60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ajpath.2017.12.009","article-title":"Syndecan-1 controls lung tumorigenesis by regulating miRNAs packaged in exosomes","volume":"188","author":"Parimon","year":"2018","journal-title":"Am J Pathol"},{"key":"2025120520004111000_73.10.636.61","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.18632\/oncotarget.14369","article-title":"Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2025120520004111000_73.10.636.62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/jcm8020131","article-title":"Prognostic role of circulating miRNAs in early-stage non-small cell lung cancer","volume":"8","author":"Ulivi","year":"2019","journal-title":"JCM"},{"key":"2025120520004111000_73.10.636.63","first-page":"1661","article-title":"Exosome-Mediated cell-cell communication in tumor progression","volume":"8","author":"Wan","year":"2018","journal-title":"Am J Cancer Res"},{"key":"2025120520004111000_73.10.636.64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2015.10.011","article-title":"Stat3-Regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells","volume":"370","author":"Liu","year":"2016","journal-title":"Cancer Lett"},{"key":"2025120520004111000_73.10.636.65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13046-018-0901-5","article-title":"The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications","volume":"37","author":"Zheng","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2025120520004111000_73.10.636.66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.gene.2018.05.008","article-title":"Lung adenocarcinoma cell-derived exosomal miR-21 facilitates osteoclastogenesis","volume":"666","author":"Xu","year":"2018","journal-title":"Gene"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-206420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:00:57Z","timestamp":1764993657000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-206420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":66,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,18]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jclinpath-2019-206420"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-206420","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}